Regeneron Beats Q3 Estimates on Dupixent Growth Plans Resubmit Eylea Application

Regeneron Pharmaceuticals has demonstrated strong financial performance in 2025, driven by its leading drugs Eylea and Dupixent. Eylea, primarily used for wet age-related macular degeneration, is transitioning sales from the original dose to the higher-dose Eylea HD, which has shown increased demand despite some competition and affordability challenges. The company's third-quarter earnings surpassed Wall Street expectations, with total revenues rising due to higher sales of Eylea HD and Dupixent, although original-dose Eylea sales declined in the U.S. Regulatory setbacks have delayed approval for the pre-filled syringe version of Eylea HD, but the company plans to resubmit by early 2026, aiming for FDA approval midyear. Analysts maintain a positive outlook on Regeneron, citing the company's strong pipeline, potential label expansions for Eylea HD, and ongoing growth in Dupixent sales, reinforcing Buy ratings with price targets between $767 and $800. Despite some stock underperformance relative to the biotech sector, Regeneron's strategic focus and earnings stability support optimism for future revenue expansion.